ArticleOncotarget2015
Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.Histology and histopathology · 2020Pooled it
- Association of different treatment modalities for rectal cancer and second primary urinary system neoplasms, findings from SEER.Scientific reports · 2025Article
- Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study.BMC research notes · 2025Article
- Recent advances in understanding the role of sex hormone receptors in urothelial cancer.Oncology research · 2025Review
- Bladder cancer incidence and mortality among men with and without castration therapy for prostate cancer - a nation-wide cohort study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.Cancer medicine · 2024Article
- The androgen receptor in bladder cancer.Nature reviews. Urology · 2023Review
- Increased risk of bladder cancer in young adult men with hyperlipidemia: A population-based cohort study.Medicine · 2021Article
- High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.Life (Basel, Switzerland) · 2021Article
- The Role of Androgens and Androgen Receptor in Human Bladder Cancer.Biomolecules · 2021Review
- Advances in bladder cancer biology and therapy.Nature reviews. Cancer · 2021Review
- The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.Translational cancer research · 2020Review
- Review
- Article
- Dihydrotestosterone increases the risk of bladder cancer in men.Human cell · 2019Article
- Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder.Pathology oncology research : POR · 2019Article
- The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer.World journal of urology · 2019Article
- High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis.Cancer management and research · 2019Review
- Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer (BC). We investigated the incidence, clinicopathological characteristics, and prognosis of BC after radiotherapy, surgical therapy, and primary androgen-deprivation therapy (ADT) for prostate cancer. This study included 1,334 Japanese patients with prostate cancer treated with radiotherapy (n=631), surgical therapy (n=437), and primary ADT (n=266). During the median follow-up period of 51.2, 44.8, and 45.5 months, secondary BC occurred in 14 (2.2%), 5 (1.1%), and 0 (0%) of patients with prostate cancer treated with radiotherapy, surgical therapy, and primary ADT, respectively. The 10-year BC-free survival rate was 91.3% in the radiotherapy group, 97.4% in the surgical therapy group, and 100% in the primary ADT group. The rates of intravesical recurrence, progression to muscle-invasive BC, and BC-specific death might be higher in secondary BC after radiotherapy compared with after surgical therapy. There was a significant difference in the incidence of secondary BC among different therapeutic modalities for prostate cancer in Japanese men, indicating significantly lower comorbidity rates of secondary BC after primary ADT for prostate cancer compared with radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.